Skip to content

Study · Ex vivo tissue · 2023

2 results

Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection.

Minutolo A, Petrone V, Fanelli M, Maracchioni C, Giudice M, Teti E, Coppola L, Sorace C, Iannetta M, Tony Miele M, Bernardini S, Mastino A and 7 more

Show all authors

Sinibaldi Vallebona P, Balestrieri E, Andreoni M, Sarmati L, Grelli S, Garaci E, Matteucci C

International immunopharmacology22 Mar 2023Cited by 11 (Europe PMC)

PMID36989892 (opens in a new tab)PMCIDPMC10030336 (opens in a new tab)DOI10.1016/j.intimp.2023.110055 (opens in a new tab)PepBankPUB-36989892
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueEfficacy outcome

    In an ex vivo study of lymphocytes from individuals with PASC and a chronically altered immune response, Tα1 improved the restoration of an appropriate immune response.

    In plain wordsIn lab tests on cells from long COVID donors, thymosin alpha‑1 helped restore a more appropriate immune response.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedRestoration of an appropriate immune response
    Study

    humann: not reported in source

    Lymphocytes from individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), ex vivo
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    in PASC individuals with a chronically altered immune response, Tα1 improve the restoration of an appropriate response
    1 context sentence
    Summary · context
    Persistent dysregulation with depletion of naive B and T cell subpopulations and expansion of memory T cells suggest a chronic stimulation of the immune response in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC).
  2. 02LabEx vivo tissueEfficacy outcome

    In the ex vivo PASC study, the Tα1 restoring effect was most evident in people with more severe acute illness needing respiratory support and in those with specific systemic and psychiatric symptoms.

    In plain wordsIn lab tests, the effect of thymosin alpha‑1 was strongest in cells from donors with severe acute COVID-19 or certain long-term symptoms.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedRestoration of immune response by PASC subgroup
    Study

    humann: not reported in source

    Lymphocytes from individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), ex vivo
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    most evident in those with more severe illness and who need respiratory support during acute phase, and in those with specific systemic and psychiatric symptoms of PASC
    1 context sentence
    Summary · context
    Persistent dysregulation with depletion of naive B and T cell subpopulations and expansion of memory T cells suggest a chronic stimulation of the immune response in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.